515-40-2

应用筛选条件

关键词:'515-40-2'

显示 1-9 共 9 条结果关于 "515-40-2" 范围论文

Meta-analysis of three diabetes population studies: association of inactive ALDH2 genotype with maternal inheritance of diabetes.

C Murata et al.

Diabetes research and clinical practice, 66 Suppl 1, S145-S147 (2004-11-27)

To date, there have been three population studies that examined the association of mitochondrial aldehyde dehydrogenase 2 (ALDH2) genotype with inheritance of diabetes. Here, we summarize the results by meta-analysis. The study 1 consisted of 212 type 2 diabetics who

A new C-terminal hERG mutation A915fs+47X associated with symptomatic LQT2 and auditory-trigger syncope.

Georges Christé et al.

Heart rhythm, 5(11), 1577-1586 (2008-11-06)

A novel mutation of hERG (A915fs+47X) was discovered in a 32-year-old woman with torsades de pointes, long QTc interval (515 ms), and syncope upon auditory trigger. We explored whether the properties of this mutation could explain the pathology. Whole-cell A915fs+47X

Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.

G Dent et al.

The Journal of pharmacology and experimental therapeutics, 271(3), 1167-1174 (1994-12-01)

The cyclic AMP phosphodiesterase (PDE) III/IV inhibitor, zardaverine, and the PDE IV-selective inhibitor, rolipram, both caused concentration-dependent inhibition of opsonized zymosan-stimulated superoxide anion generation by purified human peripheral blood eosinophils with approximate IC50 values of 30 and 40 microM, respectively.

Molecular cloning of chick cardiac muscle tensin. Full-length cDNA sequence, expression, and characterization.

S H Lo et al.

The Journal of biological chemistry, 269(35), 22310-22319 (1994-09-02)

Here we describe the molecular cloning of 7.1-kilobase cDNA encoding chick cardiac muscle tensin. It contains an open reading frame of 1,744 amino acid (aa) residues. Sequence analysis reveals that, in addition to the previously noted SH2 domain (Davis, S.

Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients.

Chen-Chung Fu et al.

Acta diabetologica, 46(2), 127-134 (2008-10-15)

To investigate the relationship of micro-albuminuria with C-reactive protein (CRP) and hyperuricemia in Chinese patients with type 2 diabetes. All patients with type 2 diabetes, 40 years old and over were recruited consecutively from diabetic clinics at a medical center.

Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma.

Stewart C Whitman et al.

Circulation research, 90(2), E34-E38 (2002-02-09)

We have previously shown that interferon-gamma (IFN-gamma) is a potent enhancer of atherogenesis. Interleukin-18 (IL-18) promotes inflammatory responses through release of IFN-gamma, although it can also exert direct actions on other inflammatory mediators. In this present study, we determined the

High-resolution three-dimensional structure of a single zinc finger from a human enhancer binding protein in solution.

J G Omichinski et al.

Biochemistry, 29(40), 9324-9334 (1990-10-09)

The three-dimensional structure of a 30-residue synthetic peptide containing the carboxy-terminal "zinc finger" motif of a human enhancer binding protein has been determined by two-dimensional nuclear magnetic resonance (2D NMR) spectroscopy and hybrid distance geometry-dynamical simulated annealing calculations. The structure

14-3-3 Binding to Na+/H+ exchanger isoform-1 is associated with serum-dependent activation of Na+/H+ exchange.

S Lehoux et al.

The Journal of biological chemistry, 276(19), 15794-15800 (2001-03-30)

Na(+)/H(+) exchanger isoform-1 (NHE1), the ubiquitous form of the Na(+)/H(+) exchanger, has increased activity in hypertensive patients and in animal models of hypertension. Furthermore, NHE1 is activated in cells stimulated with growth factors. We showed previously that activation of the

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Josef S Smolen et al.

Lancet (London, England), 383(9914), 321-332 (2013-10-31)

Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early

1/1